Fig. 4: Targeting autophagy increases survival of ruxolitinib-treated mice xenografted with JAK2V617F cells. | Blood Cancer Journal

Fig. 4: Targeting autophagy increases survival of ruxolitinib-treated mice xenografted with JAK2V617F cells.

From: Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms

Fig. 4

A NSG mice (n = 14 mice per group) engrafted with 2.106 HEL cells by intravenous injection were treated with vehicle or ruxolitinib (120 mg/kg/day) by oral gavage in combination or not with Lys05 (32 mg/kg/day) by intraperitoneal injection. B Fourteen days post-engraftment, seven mice per group were dissected to analyze the percentage of viable human cells (Annexin-V-, hCD45 + ) in the bone marrow by flow cytometry (n = 7 ± sem). C Their spleens were collected and weighted. Graphs represent spleen weight related to body weight for each mouse individually (left panel; n = 7 ± sem). D The remaining seven mice per group were used for overall survival analysis and Kaplan-Meier survival curves of engrafted mice are shown (n = 7 ± sem).

Back to article page